On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. After all, it's been less than a year since regulators in the U.S. and E.U. approved its ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.